Noticeably, these ligands, in particular PVR, are potential prognostic markers in AML (53, 54), MM (55), hepatocellular carcinoma (56), and bladder urothelial carcinoma (BLCA) (57). The gene discussed is PVR; the disease is bladder transitional cell carcinoma.